Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting FGFR inhibition in cholangiocarcinoma
Lipika Goyal, Sarinya Kongpetch, Valerie Crolley, et al.
Cancer Treatment Reviews (2021) Vol. 95, pp. 102170-102170
Open Access | Times Cited: 135

Showing 1-25 of 135 citing articles:

Clinical treatment of cholangiocarcinoma: an updated comprehensive review
Alessandra Elvevi, Alice Laffusa, Miki Scaravaglio, et al.
Annals of Hepatology (2022) Vol. 27, Iss. 5, pp. 100737-100737
Open Access | Times Cited: 89
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity acrossFGFR2Alterations and Resistance Mutations
Vivek Subbiah, Vaibhav Sahai, Dejan Maglic, et al.
Cancer Discovery (2023) Vol. 13, Iss. 9, pp. 2012-2031
Open Access | Times Cited: 65
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2
Heike Schönherr, Pelin Ayaz, Alexander M. Taylor, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 6
Open Access | Times Cited: 21
Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial
Jordi Rodón, Silvia Damian, Muhammad Furqan, et al.
Nature Medicine (2024) Vol. 30, Iss. 6, pp. 1645-1654
Open Access | Times Cited: 17
Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma
Taek Chung, Young Nyun Park
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 49
Precision medicine: Ray of hope in overcoming cancer multidrug resistance
Pankaj Musyuni, Jing Bai, Afsana Sheikh, et al.
Drug Resistance Updates (2022) Vol. 65, pp. 100889-100889
Closed Access | Times Cited: 39
Clinical management of intrahepatic cholangiocarcinoma: surgical approaches and systemic therapies
Samantha M. Ruff, Timothy M. Pawlik
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 9
The Application of Inorganic Nanoparticles in Molecular Targeted Cancer Therapy: EGFR Targeting
Meng Sun, Ting Wang, Lei‐Jiao Li, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 46
Wnt-TCF7-SOX9 axis promotes cholangiocarcinoma proliferation and pemigatinib resistance in a FGF7-FGFR2 autocrine pathway
Zengli Liu, Jialiang Liu, Tianli Chen, et al.
Oncogene (2022) Vol. 41, Iss. 20, pp. 2885-2896
Closed Access | Times Cited: 34
Precision Medicine in Biliary Tract Cancer
Aaron J. Scott, Reya Sharman, Rachna T. Shroff
Journal of Clinical Oncology (2022) Vol. 40, Iss. 24, pp. 2716-2734
Closed Access | Times Cited: 28
New drug approvals for 2022: Synthesis and clinical applications
Shuo Yuan, Dandan Shen, Rui Jia, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 6, pp. 2352-2391
Closed Access | Times Cited: 18
Current Standards, Multidisciplinary Approaches, and Future Directions in the Management of Extrahepatic Cholangiocarcinoma
Margaret Wheless, Rajiv Agarwal, Laura W. Goff, et al.
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 1, pp. 127-160
Open Access | Times Cited: 7
Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1–4 Inhibitor: Pooled Safety Analysis of 469 Patients
Funda Meric‐Bernstam, Antoine Hollebecque, Junji Furuse, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 8, pp. 1466-1477
Open Access | Times Cited: 6
Integrative analyses of bulk and single-cell transcriptomics reveals the infiltration and crosstalk of cancer-associated fibroblasts as a novel predictor for prognosis and microenvironment remodeling in intrahepatic cholangiocarcinoma
Yanjie Zhong, Xi-Mei Luo, Fei Liu, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 6
Long Non-coding RNA DANCR in Cancer: Roles, Mechanisms, and Implications
Maoye Wang, Jianmei Gu, Xu Zhang, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 39
Resistance of Lenvatinib in Hepatocellular Carcinoma
Qiuran Xu, Dong‐Sheng Huang, Jinhui Guo, et al.
Current Cancer Drug Targets (2022) Vol. 22, Iss. 11, pp. 865-878
Closed Access | Times Cited: 25
Changing Landscape of Systemic Therapy in Biliary Tract Cancer
Edward Woods, Dat Tan Le, Bharath Kumar Jakka, et al.
Cancers (2022) Vol. 14, Iss. 9, pp. 2137-2137
Open Access | Times Cited: 24
Role of molecular genetics in the clinical management of cholangiocarcinoma
Nicola Normanno, Erika Martinelli, Davide Melisi, et al.
ESMO Open (2022) Vol. 7, Iss. 3, pp. 100505-100505
Open Access | Times Cited: 23
Role and Therapeutic Potential for Targeting Fibroblast Growth Factor 10/FGFR1 in Relapsed Rheumatoid Arthritis
Xiaohui Meng, Zechuan Chen, Teng Li, et al.
Arthritis & Rheumatology (2023) Vol. 76, Iss. 1, pp. 32-47
Open Access | Times Cited: 13
Practical guidelines for molecular testing of cholangiocarcinoma in clinical practice: Italian experts’ position paper
Matteo Fassan, Valentina Angerilli, Nicola Normanno, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 194, pp. 104224-104224
Open Access | Times Cited: 5
Degradation of AZGP1 suppresses apoptosis and facilitates cholangiocarcinoma tumorigenesis via TRIM25
Hyeseon Yun, Hong‐Rae Jeong, Do Yeon Kim, et al.
Journal of Cellular and Molecular Medicine (2024) Vol. 28, Iss. 3
Open Access | Times Cited: 4
mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation
Ye Hu, Fengxi Chen, Siwen Sun, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 4
New systemic treatment options for advanced cholangiocarcinoma
Valentina Zanuso, Giulia Tesini, Elena Valenzi, et al.
Journal of Liver Cancer (2024) Vol. 24, Iss. 2, pp. 155-170
Open Access | Times Cited: 4
The efficacy of second‐line chemotherapy for advanced biliary tract cancer: A systematic review and network meta‐analysis
Inhwan Hwang, Sang‐Ah Han, Ji Hun Jeong, et al.
Journal of Hepato-Biliary-Pancreatic Sciences (2025)
Closed Access
Discovery of BW710 as a Potent, Selective and Orally Bioavailable Fibroblast Growth Factor Receptor 2 (FGFR2) Inhibitor
Bowen Yang, Qiuju Xun, Yuan Tian, et al.
European Journal of Medicinal Chemistry (2025) Vol. 287, pp. 117339-117339
Closed Access
Page 1 - Next Page

Scroll to top